Hutchmed endometrial cancer treatment gets conditional approval in China
3rd Dec 2024 10:14
(Sharecast News) - Hutchmed China and its partner Innovent Biologics announced conditional approval from China's National Medical Products Administration (NMPA) for the combination of 'Elunate', or fruquintinib, and 'Tyvyt', or sintilimab injection, to treat advanced endometrial cancer with mismatch repair proficient (pMMR) tumours.
Read moreHutchmed partner launches Fruzaqla in Japan
22nd Nov 2024 11:54
(Sharecast News) - Hutchmed China announced the launch of 'Fruzaqla', or fruquintinib, in Japan on Friday by its partner, Takeda, following approval from Japan's Ministry of Health, Labour and Welfare in September.
Read moreHutchmed to receive $20m Fruzaqla milestone payment
31st Oct 2024 11:04
(Sharecast News) - Hutchmed China announced on Thursday that it was set to receive a $20m milestone payment from its partner Takeda, after sales of 'Fruzaqla', or fruquintinib, surpassed $200m.
Read moreHutchmed reports positive results from AstraZeneca lung cancer collaboration
16th Oct 2024 11:41
(Sharecast News) - Hutchmed China announced positive results from its Savannah phase two trial on Wednesday, which studied the combination of 'Tagrisso', or osimertinib, and 'Orpathys', or savolitinib, in treating patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC), who had high levels of MET overexpression or amplification and whose disease progressed after treatment with Tagrisso.
Read moreHutchmed partner Takeda gets Japanese approval for Fruzaqla
24th Sep 2024 11:06
(Sharecast News) - Hutchmed China announced on Tuesday that its partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) to manufacture and market 'Fruzaqla', or fruquintinib, for the treatment of previously-treated metastatic colorectal cancer (CRC).
Read moreHutchmed to present new and updated clinical trial data
9th Sep 2024 12:31
(Sharecast News) - Hutchmed China has announced that it would present new and updated clinical trial data at two major oncology conferences - the 2024 World Conference on Lung Cancer (WCLC24) in San Diego, and the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.
Read moreHutchmed withdraws supplemental new drug application in China
30th Aug 2024 10:53
(Sharecast News) - Hutchmed China has voluntarily withdrawn its supplemental new drug application (NDA) in China for the use of fruquintinib in combination with paclitaxel for second-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma, it announced on Friday.
Read moreOncology revenue drives first-half growth for Hutchmed
31st Jul 2024 12:16
(Sharecast News) - Hutchmed China reported a robust set of first-half financial results on Wednesday, underpinned by significant growth in oncology product revenue and a solid cash position to support ongoing expansion.
Read moreHutchmed gets tazemetostat new drug application approved in China
4th Jul 2024 14:03
(Sharecast News) - Hutchmed China announced on Thursday that the China National Medical Products Administration (NMPA) has accepted its new drug application (NDA) for tazemetostat, granting it priority review for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL).
Read moreHutchmed partner gets European approval for fruqintinib
24th Jun 2024 12:20
(Sharecast News) - Hutchmed China announced on Monday that its partner Takeda has received approval from the European Commission for 'Fruzaqla', or fruquintinib, as a monotherapy for adult patients with metastatic colorectal cancer (CRC).
Read moreHutchmed publishes positive sovleplenib trial results
17th Jun 2024 09:28
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Read moreHutchmed China launches two cancer treatment trials
14th May 2024 11:42
(Sharecast News) - Hutchmed China announced the start of two significant clinical trials on Tuesday, aimed at addressing critical unmet needs in cancer treatment.
Read moreHutchmed China to make several presentations at cancer research meeting
5th Apr 2024 11:54
(Sharecast News) - Hutchmed China announced the upcoming presentation of new and updated data from various studies featuring compounds it had discovered on Friday, at the American Association of Cancer Research (AACR) annual meeting from 5 to 10 April in San Diego, California.
Read moreHutchmed endometrial cancer treatment gets priority review in China
2nd Apr 2024 12:11
(Sharecast News) - Hutchmed China announced the acceptance and granting of priority review by the China National Medical Products Administration (NMPA) for a new drug application combining fruquintinib and sintilimab for the treatment of advanced endometrial cancer on Tuesday.
Read moreHutchmed cancer treatment indication accepted for review in China
28th Mar 2024 13:02
(Sharecast News) - Hutchmed China announced a significant milestone in its cancer treatment work on Thursday, with the supplemental new drug application (sNDA) for savolitinib had been accepted for review by the China National Medical Products Administration (NMPA).
Read more